Anti-Human EGFL7 Recombinant Antibody (TAB-902)

Customer Review

There are currently no Customer reviews or questions for TAB-902. Click the button above to contact us or submit your feedback about this product.

Laura Scott
18.Oct,23

Great for EGFL7 Studies

The Anti-Human EGFL7 Therapeutic Antibody (Parsatuzumab) has been excellent for our EGFL7 studies. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

David Young
05.Dec,22

Reliable in Multiple Assays

We incorporated this antibody into our Western blot and immunoassays, and it has been a great asset. The specificity for EGFL7 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Megan Martinez
09.Jul,21

Consistent High-Quality Results

This antibody has proven to be consistent and high-quality in our various assays. The reproducible results and strong affinity for EGFL7 have significantly improved our experiments, making it a crucial part of our research toolkit. The consistent performance has greatly enhanced our data quality.

Q&As

1. Is the anti-Human EGFL7 therapeutic antibody Parsatuzumab suitable for use in Western blotting?

   A: Yes, the anti-Human EGFL7 therapeutic antibody Parsatuzumab (TAB-902) is suitable for use in Western blotting. It provides specific binding to EGFL7, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-Human EGFL7 therapeutic antibody Parsatuzumab?

   A: The recommended storage condition for the anti-Human EGFL7 therapeutic antibody Parsatuzumab (TAB-902) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-Human EGFL7 therapeutic antibody Parsatuzumab be used in immunoprecipitation assays?

   A: Yes, the anti-Human EGFL7 therapeutic antibody Parsatuzumab (TAB-902) can be used in immunoprecipitation assays. It provides specific binding to EGFL7, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-Human EGFL7 therapeutic antibody Parsatuzumab effective in ELISA applications?

   A: Yes, the anti-Human EGFL7 therapeutic antibody Parsatuzumab (TAB-902) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of EGFL7.

5. What is the optimal dilution for using the anti-Human EGFL7 therapeutic antibody Parsatuzumab in immunofluorescence?

   A: The optimal dilution for using the anti-Human EGFL7 therapeutic antibody Parsatuzumab (TAB-902) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Bill, Marius, et al. "EGFL7 antagonizes NOTCH signaling and represents a novel therapeutic target in acute myeloid leukemia." Clinical Cancer Research 26.3 (2020): 669-678. https://doi.org/10.1158/1078-0432.CCR-19-2479
   This study investigated the role of EGF-like domain 7 (EGFL7) in acute myeloid leukemia (AML) and its potential as a therapeutic target. The researchers found that EGFL7 is upregulated in AML and contributes to leukemogenesis by antagonizing NOTCH signaling. Through various in vitro and in vivo experiments, the study demonstrated that blocking EGFL7 with an anti-EGFL7 antibody (parsatuzumab) reactivated NOTCH signaling, leading to increased differentiation and apoptosis of leukemic cells. Additionally, anti-EGFL7 treatment prolonged the survival of AML mouse models, indicating the potential of EGFL7 as a novel therapeutic target for AML.
   Creative Biolabs provided the anti-EGFL7 therapeutic antibody, parsatuzumab (Cat#: TAB-902), which was critical for the experiments that demonstrated the reactivation of NOTCH signaling and the resulting differentiation and apoptosis of AML cells. The use of parsatuzumab allowed the researchers to validate the therapeutic potential of targeting EGFL7 in AML and provided significant insights into the molecular mechanisms by which EGFL7 influences leukemogenesis. This contribution was essential for establishing EGFL7 as a viable target for AML treatment.
2. Papaioannou, Dimitrios, et al. "Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia." Proceedings of the National Academy of Sciences 114.23 (2017): E4641-E4647. https://doi.org/10.1073/pnas.1703142114
   This research investigates the prognostic and biological significance of Epithelial Growth Factor-Like 7 (EGFL7) in acute myeloid leukemia (AML). The study demonstrates that EGFL7 mRNA and protein expression levels are significantly increased in AML blasts compared to normal bone marrow cells. High EGFL7 expression was associated with lower complete remission rates and shorter event-free and overall survival in both younger and older patients with cytogenetically normal AML. Importantly, the research reveals that AML blasts secrete EGFL7 protein, with higher levels detected in sera from AML patients compared to healthy controls. Treatment of AML blasts with recombinant EGFL7 in vitro resulted in increased leukemic blast cell growth and phosphorylated AKT levels, while EGFL7 blockade with an anti-EGFL7 antibody reduced growth potential and viability of AML cells.
   Creative Biolabs provided humanized murine monoclonal antibody that binds to the EGFL7 protein and inhibits its function (parsatuzumab) for the study. The antibody would be crucial for the experiments demonstrating EGFL7's role in AML blast proliferation and for the therapeutic blockade studies. The availability of high-quality, validated reagents targeting EGFL7 would enable researchers to effectively investigate the autocrine mechanism by which EGFL7 supports leukemic blast growth and evaluate the potential of EGFL7-targeted therapy in AML treatment.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-902, RRID: AB_3112018)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Publications

Our products have been used extensively by scientists all over the world to accelerate their life science research. Here, we present a collection of publications that cite this product.

Bill, Marius, et al. "EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia." Clinical Cancer Research (2019).

Biosimilar Overview

Please refer to Parsatuzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Parsatuzumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

See other products for "EGFL7"

Select a product category from the dropdown menu below to view related products.